WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML)

Anticancer Res. 2005 May-Jun;25(3B):1841-50.

Abstract

Cytokine stimulation induces proliferation and growth of acute myeloid leukemia (AML) blasts and high levels of cytokines have been associated with poor prognosis in AML. The Jak-Stat pathway constitutes a major mediator of cytokine activity. We investigated whether WP-1034, a novel Jak-Stat inhibitor, is active against AML blasts. OCIM2 and fresh AML cells were incubated with 1 to 6 microM WP-1034 to determine its effect on proliferation. WP-1034 effectively inhibited proliferation of OCIM2 cells and fresh AML samples. We then analyzed the expressions of Stat 1, 3, and 5, as well as Phospho-Stat 1, 3, and 5 by Western immunoblotting after incubation of OCIM2 cells without and with 1 to 10 microM WP-1034 for 2 hours, and at 5 microM from 20 minutes up to 4 hours and found that WP-1034 blocked Stat 3 and 5 activation. Analysis of cell cycle status by PI staining and flow cytometry showed that WP-1034 caused cell cycle arrest of OCIM2 cells in sub-Go phase. We then evaluated the induction of apoptosis of OCIM2 cells following incubation with WP-1034 at 3 to 6 microM by annexin V-CY5 assay and analyzed caspase 3 and PARP cleavage using Western immunoblotting. We found that WP-1034 induced apoptosis of OCIM2 cells and that induction of apoptosis involved cleavage of caspase 3 and the DNA repair enzyme poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP). Taken together, our data suggest that WP-1034 is a potent inhibitor of AML cell proliferation by inhibition of Stat 3 and 5 and induction of caspase-dependent apoptosis.

MeSH terms

  • Acrylamides / pharmacology*
  • Acute Disease
  • Adult
  • Aged
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Caspase 3
  • Caspases / metabolism
  • Cell Cycle / drug effects
  • Cell Growth Processes / drug effects
  • Cell Line, Tumor
  • DNA-Binding Proteins / antagonists & inhibitors*
  • Enzyme Activation / drug effects
  • Female
  • Humans
  • Janus Kinase 1
  • Leukemia, Erythroblastic, Acute / drug therapy
  • Leukemia, Erythroblastic, Acute / enzymology
  • Leukemia, Erythroblastic, Acute / pathology
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / enzymology
  • Leukemia, Myeloid / pathology
  • Male
  • Milk Proteins / antagonists & inhibitors*
  • Nitriles / pharmacology*
  • Protein Kinase Inhibitors / pharmacology
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • STAT3 Transcription Factor
  • STAT5 Transcription Factor
  • Signal Transduction / drug effects
  • Trans-Activators / antagonists & inhibitors*

Substances

  • Acrylamides
  • Antineoplastic Agents
  • DNA-Binding Proteins
  • Milk Proteins
  • Nitriles
  • Protein Kinase Inhibitors
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • STAT5 Transcription Factor
  • Trans-Activators
  • WP-1034
  • Protein-Tyrosine Kinases
  • JAK1 protein, human
  • Janus Kinase 1
  • CASP3 protein, human
  • Caspase 3
  • Caspases